Inhibin B was not increased upon dgx treatment in prostate cancer patients (19) or in healthy volunteers in response to testosterone-stimulating human chorionic gonadotropin treatment (20) but the persistent decline in inhibin B in a testosterone/progestin male contraceptive trial following a rapid drop of FSH levels is in line with the animal data and our current findings (21). Here, BRD2 is linked to prostate cancer.